Recombinant Human IL-36β, 157a.a. (Recombinant Human Interleukin-36β, 157a.a.; rHuIL-36β, 157a.a.);重组人白细胞介素36β,157a.a.
Synonyms
IL36B; IL1F8; IL1H2
Purity
>97% by SDS-PAGE and HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The specific activity is determined by its binding ability in a functional ELISA. Immobilized rHuIL-36β at 1μg/ml can bind recombinant human IL-1 Rrp2 Fc Chimera with a range of 0.15-5μg/ml.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH7.4.
Endotoxin
Less than 1EU/μg of rHuIL-36β, 157a.a. as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin. Furthermore, it can stimulate production of interleukin-6 and interleukin-8 in synovial fibroblasts, articular chondrocytes and mature adipocytes. Two alternatively spliced transcript variants encode distinct (164 or 157 residues) protein isoforms that differ in their C-terminal 70 amino acid residues have been reported and IL-36β isoform 2 is synthesized as a 157a.a. protein. Specifically, human IL-36β shares low sequence identity with IL-1β, IL-36RA, IL-36α and IL-36γ.